TherapeuticsMD issues 312,525 shares to Rubric Capital for $1.15M; amends bylaws

TherapeuticsMD, Inc.

Issued 312,525 shares at $3.6797/share to Rubric Capital Management on June 29, 2023, gross proceeds $1,149,998.
Stockholders approved the Subscription Agreement at the June 26, 2023 annual meeting under Nasdaq rules.
Board amended bylaws to exempt the Rubric Capital deal from Nevada control share acquisition statutes.
Shares sold in private placement exempt from registration under Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TherapeuticsMD, Inc.: An amendment to the bylaws was adopted to opt out of Nevada's control share acquisition statutes with respect to the Subscription Agreement and related transactions (effective 2023-06-29).

Change: bylaw amendment
Effective: 2023-06-29

Exact text from the filing

Amendment to the Bylaws Effective June 29, 2023, the Board of Directors of the Company adopted and approved an amendment to the Bylaws of the Company, as previously amended (the “Bylaw Amendment”), to render the provisions of Nevada’s acquisition of controlling interest statutes (NRS 78.378 through 78.3793, inclusive) not applicable to the Subscription Agreement, the acquisition of any shares of the Company’s capital stock thereunder or the consummation of any transactions contemplated thereby, or by the other documents, instruments and arrangements contemplated by the Subscription Agreement.

View on SEC.gov

37 governance changes filed in the last 30 days. Browse all governance changes →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-182808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.